Olaratumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Stromal Tumor (GIST)
Conditions
Gastrointestinal Stromal Tumor (GIST)
Trial Timeline
Aug 1, 2011 → Nov 1, 2012
NCT ID
NCT01316263About Olaratumab
Olaratumab is a phase 2 stage product being developed by Eli Lilly for Gastrointestinal Stromal Tumor (GIST). The current trial status is terminated. This product is registered under clinical trial identifier NCT01316263. Target conditions include Gastrointestinal Stromal Tumor (GIST).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03994627 | Pre-clinical | Completed |
| NCT01316263 | Phase 2 | Terminated |
| NCT01199822 | Phase 1 | Completed |
Competing Products
20 competing products in Gastrointestinal Stromal Tumor (GIST)